
BackgroundIntravenous thrombolysis (IVT) for patients treated with mechanical thrombectomy (MT) for proximal occlusions has recently been questioned through randomized trials. However, few patients with M2 occlusions were included. We investigated the influence of prior IVT for patients presenting M2 occlusions treated with MT in comparison with MT alone.MethodsWe conducted a retrospective analysis of the Endovascular Treatment in Ischemic Stroke (ETIS) registry, a multicenter observational study. Data from consecutive patients treated with MT for M2 occlusions between January 2015 and January 2022 at 26 comprehensive stroke centers were analyzed. The primary endpoint was 90-day modified Rankin Scale score of 0–2. Outcomes were compared using propensity score approaches. We also performed sensitivity analysis in relevant subgroups of patients.ResultsAmong 1132 patients with M2 occlusions treated with MT, 570 received prior IVT. The two groups were comparable after propensity analysis. The rate of favorable functional outcome was significantly higher in the IVT+MT group compared with the MT alone group (59.8% vs 44.7%; adjusted OR 1.38, 95% CI 1.10 to 1.75, P=0.008). Hemorrhagic and procedural complications were similar in both groups. In sensitivity analysis excluding patients with anticoagulation treatment, favorable recanalization was more frequent in the IVT+MT group (OR 1.37, 95% CI 1.11 to 1.70, P=0.004).ConclusionsIn cases of M2 occlusions, prior IVT combined with MT resulted in better functional outcome than MT alone, without increasing the rate of hemorrhagic or procedural complications. These results suggest the benefit of IVT in patients undergoing MT for M2 occlusions.
Mechanical Thrombolysis, [SDV]Life Sciences [q-bio], 610, Sciences de la santé humaine, Brain Ischemia, Thrombolytic Therapy/methods, Fibrinolytic Agents, Neurologie, Humans, Thrombolytic Therapy, Registries, Human health sciences, Ischemic Stroke/surgery, Ischemic Stroke, Thrombectomy, Retrospective Studies, Fibrinolytic Agents/therapeutic use, Mechanical Thrombolysis/methods, Brain Ischemia/drug therapy, Thrombolysis, [SDV] Life Sciences [q-bio], Stroke, Brain Ischemia/surgery, Treatment Outcome, Neurology, Thrombectomy/methods, Stroke/surgery, Surgery, Ischemic Stroke/drug therapy, Neurology (clinical), Stroke/drug therapy
Mechanical Thrombolysis, [SDV]Life Sciences [q-bio], 610, Sciences de la santé humaine, Brain Ischemia, Thrombolytic Therapy/methods, Fibrinolytic Agents, Neurologie, Humans, Thrombolytic Therapy, Registries, Human health sciences, Ischemic Stroke/surgery, Ischemic Stroke, Thrombectomy, Retrospective Studies, Fibrinolytic Agents/therapeutic use, Mechanical Thrombolysis/methods, Brain Ischemia/drug therapy, Thrombolysis, [SDV] Life Sciences [q-bio], Stroke, Brain Ischemia/surgery, Treatment Outcome, Neurology, Thrombectomy/methods, Stroke/surgery, Surgery, Ischemic Stroke/drug therapy, Neurology (clinical), Stroke/drug therapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
